Avacta News Feed

Avacta boss Alastair Smith anticipating 2018 to be a very significant year

Alastair Smith, chief executive of Avacta Group Plc ( LON:AVCT ) tells Proactive the past year had been one of significant progress – both for the development of a potential drug based on its platform and its use by other customers in research and diagnostics. Smith says they've made excellent progress with their potential...

Avacta building on 'significant' commercial momentum for Affimer technology

Dr Alastair Smith, chief executive of Avacta Group Plc ( LON:AVCT ), tells Proactive they've been making significant technical and commercial headway with their Affimer technology, as part of the firm's trading update for the year to the end of July 2017. ''It's been 12 months of significant de-risking of the therapeutic...

Pages